您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Misonidazole
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Misonidazole
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Misonidazole图片
CAS NO:13551-87-6
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品介绍
Misonidazole (Ro 7-0582; SR 1354) 是一种缺氧肿瘤细胞放射增敏剂。
Cas No.13551-87-6
别名米索硝唑,NSC 261037,Ro 7-0582,SR 1354
化学名α-(methoxymethyl)-2-nitro-1H-imidazole-1-ethanol
Canonical SMILESOC(COC)CN1C=CN=C1[N+]([O-])=O
分子式C7H11N3O4
分子量201.2
溶解度≤5mg/ml in ethanol;15mg/ml in DMSO;15mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Misonidazole (MISO), a hypoxic cell radiosensitizer, is selectively metabolized by hypoxic cells to reactive products that bind covalently to cellular constituents. The drug also possesses a substantial cytotoxic effect, independent of radiation, which is selectively expressed in hypoxic cells. Misonidazole may be cytotoxic to the normal hypoxic tissues in the human body, making this became a major concern in the clinical application of the drug. Misonidazole leads to strand breaks in cellular DNA and those cells which fail to survive also fail to repair these strand breaks. Misonidazole depletes intracellular glutathione and is more toxic in glutathione depleted cells. The depletion is time, temperature, drug concentration and cell line dependent.

In vitro: In cultured CHO cells, pretreatment with 5 mM MISO for 2 hr exihibited the marginal toxicity [2].

In vivo: Pretreatment with misonidazole (MISO) enhanced the number of cross-links formed in a fibrosarcoma and in the spleen and gut of mice for periods up to 48 h following a single injection of melphalan (MEL). MISO pretreatment could result in a greater amount of binding of MEL to DNA at early times after injection. MISO may exert its affect by inhibiting the repair of cross-links or monoadducts at early times post-injection [3].

Clinical trials: Various dose schedules of misonidazole have proven to be tolerable, with a moderate incidence of nausea and vomiting and mild peripheral neuropathy, and a low incidence of more severe peripheral neuropathy or central neuropathy [4].

References:
[1] Josephy P D, Palcic B, Skarsgard L D.  Ascorbate-enhanced cytotoxicity of misonidazole[J]. Nature, 1978, 271(5643): 370-372.
[2]Taylor Y C, Bump E A, Brown J M.  Studies on the mechanism of chemosensitization by misonidazole in vitro[J]. International Journal of Radiation Oncology Biology Physics, 1982, 8(3-4): 705-708.
[3] Murray D, Meyn R E.  Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo[J]. British journal of cancer, 1983, 47(2): 195.
[4] Wasserman T H, Stetz J A, Phillips T L.  Clinical trials of misonidazole in the United States[J]. Cancer clinical trials, 1980, 4(1): 7-16.